Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Aug 16, 2022; 10(23): 8141-8151
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8141
Table 1 Association between carbohydrate antigen 125 and clinical features in 108 sarcoidosis patients
Characteristics
Total patients
CA125 ≤ 35 U/mL
CA125 > 35 U/mL
χ2/Z value
P value
Total, n1081692
Age at diagnosis in yr51.00 (44.00, 55.75)53.50 (48.25, 56.50)50.00 (43.00, 55.75)-1.1080.268
Sex1.000
Male31 (28.7)5 (31.3)26 (28.3)
Female77 (71.3)11 (68.8)66 (71.7)
Clinical presentation
Dyspnea76 (70.4)10 (62.5)66 (71.7)0.2030.652
Cough58 (53.7)8 (50.0)50 (54.3)0.1040.748
Erythema nodosum27 (25.0)7 (43.8)20 (21.7)2.4460.118
Fever37 (34.3)6 (37.5)31 (33.7)0.0880.767
Arthralgia/arthritis21 (19.4)4 (25.0)17 (18.5)0.0710.790
Fatigue25 (23.1)6 (37.5)19 (20.7)1.3310.249
Organ involvement
Pulmonary96 (88.9)12 (75)59 (64.1)0.7150.398
Extra thoracic lymph nodes30 (27.8)4 (25.0)26 (28.3)0.0001.000
Ocular12 (11.1)2 (12.5)10 (10.9)0.0001.000
Liver9 (8.3)1 (6.3)7 (7.6)0.0001.000
Cardiac 8 (7.4)0 (0)9 (9.8)0.6670.414
Pleural effusion11 (10.2)2 (12.5)9 (9.8)0.0001.000
Scadding classification of chest radiography4.6030.171
02 (1.9)0 (0)2 (2.2)
I35 (32.4)2 (12.5)33 (35.9)
II51 (47.2)9 (56.3)42 (45.7)
III20 (18.5)5 (31.3)15 (16.3)
Natural history2.3570.125
Asymptomatic or have acute symptoms with spontaneous resolution75 (69.4)8 (50)67 (72.8)
Relapse or progressive course33 (30.6)8 (50)25 (27.2)
Treatment2.7600.314
Oral steroids34 (31.5)5 (31.3)29 (31.5)
ICS43 (39.8)3 (18.8)23 (25)
Oral steroids and methotrexate26 (24.1)6 (37.5)37 (40.2)
Others5 (4.6)2 (12.5)3 (3.3)
Pulmonary function tests % of predicted
TLC86.45 (80.15, 93.70)85.70 (79.23, 95.38)86.50 (80.05, 93.55)-0.0610.952
RV86.45 (80.05, 93.90)91.30 (71.50, 97.58)85.00 (63.00, 100.10)-0.2080.835
FEV185.40 (79.70, 98.33)85.85 (78.30, 92.08)85.40 (79.73, 98.60)-0.5110.610
FVC78.25 (73.30, 86.60)84.05 (76.98, 89.83)77.80 (73.03, 84.48)-2.0280.043a
FEV1/FVC78.91 (73.68, 85.13)78.44 (70.54, 95.28)78.91 (73.68, 85.12)-0.4760.634
DLCO80.60 (73.58, 96.35)78.20 (71.30, 90.98)81.40 (74.10, 97.00)-0.6970.486
Peripheral blood counts
WBC ×109/L6.29 (5.35, 7.62)6.15 (5.52, 7.56)6.29 (5.16, 7.62)-0.2030.839
NLR2.76 (2.15, 4.01)3.74 (2.76, 4.55)2.74 (2.03, 3.85)-2.0760.038a
Serum chemistries
ALT19.0 (15.0, 30.0)17.5 (15.0, 25.5)19.0 (15.0, 30.0)-0.6280.530
AST23.00 (17.00, 32.00)22.50 (17.00, 36.25)23.00 (17.00, 28.75)-0.4120.680
Cr65.00 (53.23, 76.00)66.00 (56.75, 81.50)65.00 (53.00, 75.00)-0.9780.328
ESR8.00 (5.00, 17.00)6.50 (4.25, 11.50)9.00 (5.25, 17.75)-1.4690.142
CRP1.28 (0.57, 4.60)1.58 (0.38, 2.60)1.28 (0.59, 4.98)-1.0860.277
ACE27.50 (15.25, 39.00)25.50 (15.25, 37.25)28.00 (15.25, 47.25)-0.620 0.535
BAL % cells
BAL % macrophage76.0 (65.5, 88.5)76.0 (65.0, 89.0)77.5 (65.5, 88.5)-0.2810.778
BAL % lymphocyte21.00 (8.00, 34.00)22.00 (7.25, 34.00)20.00 (8.00, 33.75)-0.4070.684
CD4+T%75.20 (61.90, 84.73)72.85 (60.85, 89.00)75.20 (62.63, 83.60)-0.3510.726
CD4/CD8 ratio5.05 (3.30, 9.50)7.05 (2.78, 9.50)4.90 (3.30, 9.50)-0.4760.634
Table 2 Binary logistic regression analysis between the sarcoidosis and health control groups
Characteristics
β
SE
Wald value
P value
OR
95%CI
Erythema nodosum0.9830.6072.6210.1052.6720.8138.785
Scadding classification of chest radiography-0.6540.4392.220.1360.520.221.229
Natural history-1.0680.5973.1940.0740.3440.1071.109
Forced vital capacity-0.0550.0254.7880.029a0.9460.90.994
ESR0.0280.0360.6130.4341.0290.9581.105
NLR-0.1450.0992.1160.1640.8650.7121.052